Revance (RVNC) and Crown Laboratories amended their Amended and Restated Merger Agreement. Under the terms of the Second Amendment, which has been unanimously approved by the Revance Board of Directors, Revance’s stockholders will receive $3.65 per share of common stock, par value $0.001 per share in cash, representing 55c or 17% per share more than the prior offer price. Crown’s tender offer has been extended until one minute past 11:59 p.m., Eastern Time, on February 4, unless the tender offer is further extended or earlier terminated. The transaction is expected to close by February 6. The outside termination date for the A&R Merger Agreement remains February 7. Crown does not intend to extend the outside termination date of the A&R Merger Agreement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVNC:
- Crown Laboratories extends tender offer to acquire Revance Therapeutics
- Class Action Filed Against Revance Therapeutics, Inc. (RVNC) – March 04, 2025 Deadline to Join – Contact Levi & Korsinsky LLP
- Disney to own 70% of Fubo, Trudeau to resign as party leader: Morning Buzz
- Teoxane announces proposal to acquire Revance for $3.60 per share in cash
- Revance price target lowered to $3 from $7 at Barclays